Welcome to our dedicated page for Protagonist Therapeutics news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Therapeutics stock.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to discover and develop novel peptide-based drugs. The company's primary focus is on creating first-in-class oral targeted therapies that inhibit biological pathways currently addressed by injectable antibody drugs. This innovative approach aims to treat significant unmet medical needs, particularly in the areas of inflammatory bowel disease (IBD) and other autoimmune diseases.
Protagonist's lead peptide product candidates, PTG-100 and PTG-200, are designed to transform treatment paradigms for conditions such as ulcerative colitis and Crohn's disease. PTG-100, an oral peptide alpha-4-beta-7 integrin antagonist, is in a global Phase 2b clinical trial for moderate-to-severe ulcerative colitis. PTG-200, a first-in-class oral interleukin-23 receptor antagonist, is also progressing through clinical trials.
Another key asset, JNJ-2113 (formerly PN-235), achieved primary and secondary endpoints in the Phase 2b FRONTIER 1 trial for moderate-to-severe plaque psoriasis. This drug is part of an extensive clinical development program, including multiple Phase 3 studies under the ICONIC program. JNJ-2113 is also being evaluated in a Phase 2b ANTHEM-UC study for ulcerative colitis.
Protagonist's pipeline also includes Rusfertide (PTG-300), an injectable hepcidin mimetic currently in Phase 3 development for polycythemia vera. The REVIVE Phase 2 study demonstrated that rusfertide effectively maintains hematocrit control and reduces the need for phlebotomies in patients.
The company has established significant partnerships to further its clinical programs. Notably, Protagonist collaborates with Johnson & Johnson and Takeda Pharmaceuticals to co-develop and co-commercialize its lead candidates, expanding its reach and impact in the biopharmaceutical landscape.
Protagonist continues to drive innovation with its ongoing discovery efforts, aiming to develop additional oral peptides targeting validated biological pathways. With a robust pipeline and strategic collaborations, Protagonist Therapeutics is poised to make substantial contributions to the treatment of autoimmune and hematological diseases.
Protagonist Therapeutics (Nasdaq: PTGX) announced that CEO Dinesh V. Patel will present at the 41st Annual J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco. The presentation is scheduled for January 11 at 7:30 a.m. PT, held at the Westin St. Francis. Protagonist is advancing its lead drug candidate, rusfertide, for polycythemia vera in a global Phase 3 trial, alongside a partnership with Janssen Biotech for PN-235, aimed at treating psoriasis and inflammatory bowel diseases. A webcast will be available on the company’s investor website.
Protagonist Therapeutics (Nasdaq: PTGX) announced that Dr. Dinesh V. Patel, President and CEO, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit from December 6-7, 2022. The chat is scheduled for December 6, 2022, at 11:40 a.m. ET. A webcast will be accessible for 90 days on Protagonist's Investors section. The company is advancing its lead drug candidate, rusfertide, in a global Phase 3 study for polycythemia vera, and has partnered with Janssen Biotech on PN-235 for psoriasis and inflammatory bowel disease.
Protagonist Therapeutics (PTGX) announced the granting of inducement awards to Dr. Arturo Molina, its new Chief Medical Officer, on November 15, 2022. Dr. Molina received options to purchase 127,500 shares and restricted stock units for 21,250 shares, with an exercise price of $8.04 per share. The options and RSUs will vest over four years. This award aligns with Nasdaq rules and emphasizes the company's commitment to attract key talent. Protagonist is advancing its drug candidate rusfertide in a Phase 3 study for polycythemia vera, alongside a partnership with Janssen for the development of PN-235.
Protagonist Therapeutics (Nasdaq: PTGX) continues its Phase 3 VERIFY clinical study of rusfertide for polycythemia vera (PV) amidst operational hiring challenges. Dr. Arturo Molina has been appointed as the new Chief Medical Officer to enhance clinical development efforts. The company plans to present three posters at the ASH Annual Meeting in December. Financially, Protagonist reported a net loss of $31.2 million in Q3 2022, with cash and equivalents of $267.4 million expected to cover operations through 2024. Revenue from collaboration agreements decreased significantly.
Protagonist Therapeutics (PTGX) announced that three abstracts related to its rusfertide program will be presented at the 64th Annual ASH Meeting from December 10-13, 2022, in New Orleans. The presentations include a Phase 3 study on rusfertide in patients with Polycythemia Vera (VERIFY), a Phase 2 subgroup analysis of adverse events (REVIVE), and an efficacy study of a rusfertide analog in a mouse model for hereditary hemochromatosis. Protagonist owns marketing rights to rusfertide, which is in the final stages of clinical development.
Protagonist Therapeutics has appointed Dr. Arturo Molina as Chief Medical Officer, effective November 7, 2022. Dr. Molina, an accomplished hematologist-oncologist, will lead the Phase 3 VERIFY study of rusfertide for polycythemia vera and enhance the company’s clinical and operational strategies. His prior experience includes roles at Sutro Biopharma and Johnson & Johnson, underscoring a strong track record in clinical development. The focus on rusfertide's potential to transform treatment highlights the company’s commitment to advancing innovative therapies.
Protagonist Therapeutics (Nasdaq: PTGX) announced an inducement award for newly hired Vice President of Pharmacovigilance, Dr. Pedro Oyuela, on September 15, 2022. The award includes an option to purchase 35,000 shares at an exercise price of $8.27, the closing price on the grant date. The shares will vest over four years, with 25% vesting after one year and the remainder in equal monthly installments. This grant complies with Nasdaq rules and aims to incentivize Dr. Oyuela's employment.
Protagonist Therapeutics (PTGX) reported its Q2 2022 financial results with a net loss of $41.0 million, or $0.84 per share, compared to a loss of $30.8 million in Q2 2021. The company's cash position remains strong, totaling $291.9 million, sufficient to fund operations until the end of 2024. Protagonist is advancing its Phase 3 VERIFY study of rusfertide in polycythemia vera, with 35 sites activated globally despite slower initial enrollment. Additionally, the company is pursuing clinical development for its other candidates, PN-235 and PN-943, showcasing a commitment to innovation.
Protagonist Therapeutics (PTGX) announced an inducement award granted to newly appointed Vice President, Controller, Karen Peterson, on July 15, 2022. The award includes an option to purchase 25,000 shares at an exercise price of $9.46, reflecting the closing price on that date. The stock options will vest over four years, with 25% vesting after the first year and the rest monthly thereafter. This grant aligns with Nasdaq rules and aims to incentivize Peterson's employment with the company, which focuses on peptide-based drug development, including its lead candidate rusfertide in a Phase 3 study.
Protagonist Therapeutics (Nasdaq: PTGX) announced that CEO Dinesh V. Patel, Ph.D., will present at the Jefferies Healthcare Conference in New York on June 8, 2022, at 9:30 a.m. ET. A webcast of the event will be available for 90 days on the company's Investors website.
The company is advancing peptide-based therapeutics including rusfertide, currently in trials for polycythemia vera, and PN-943, which is moving towards Phase 3 studies. Protagonist has also partnered with Janssen on oral IL-23 receptor antagonists, focusing on the development of PN-235 for psoriasis treatment.
FAQ
What is the current stock price of Protagonist Therapeutics (PTGX)?
What is the market cap of Protagonist Therapeutics (PTGX)?
What is Protagonist Therapeutics' main focus?
What are PTG-100 and PTG-200?
What is JNJ-2113?
What is rusfertide (PTG-300)?
Who are Protagonist's collaboration partners?
What recent achievements has Protagonist announced?
What is Protagonist's proprietary technology platform?
What are the latest developments in Protagonist's clinical trials?
What is the status of the rusfertide Phase 3 VERIFY trial?
Where can I find more information about Protagonist's drug candidates and clinical studies?
